CorMedix Inc. (CRMD): A Bull Case Theory [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
A surgeon holding a single-use catheter system in a public hospital, demonstrating its successful use in treating lower extremity vascular disease. Cormedix is currently navigating the commercialization of its innovative product, DefenCath, a catheter lock solution designed to significantly reduce catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Approved by the FDA in 2023, DefenCath incorporates taurolidine and heparin to prevent bacterial growth and maintain catheter patency. Its efficacy was highlighted in the pivotal LOCK-IT-100 study, which demonstrated a remarkable 71% reduction in CRBSIs compared to traditional heparin-only treatments. With the increasing prevalence of CRBSIs in hemodialysis patients, DefenCath addresses a critical need, especially given that these infections pose severe health risks, including sepsis and endocarditis, particularly in immunocompromised populations. Following its FDA approval, CorMedix has commenced sale
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. to Participate in the Truist Securities BioPharma SymposiumGlobeNewswire
- Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic [Yahoo! Finance]Yahoo! Finance
- CorMedix Inc. (NASDAQ: CRMD) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 10/30/24 - Beat
CRMD
Sec Filings
- 11/18/24 - Form 4
- 11/14/24 - Form 144
- 11/14/24 - Form SC
- CRMD's page on the SEC website